Professional Qualifications and Independence of Board Members

The Company, as a publicly listed company, has established more than three Independent Directors in accordance with the requirements of the Securities and Exchange Act and the Company's Articles of Incorporation. The number of Independent Directors accounts for no less than one-fifth of the total Board seats. In addition, the Company has established an Audit Committee composed entirely of Independent Directors to perform the duties previously exercised by Supervisors.

The Board of Directors was re-elected on June 24, 2024, and currently consists of five Directors and four Independent Directors. In assessing the independence of its Directors, the Board considers all relevant factors, including whether the Directors are able to continue raising constructive questions to management and other Board members, whether they express views independently of management and other Directors, and whether they satisfy the independence requirements set forth in Article 14-2 of the Securities and Exchange Act.

None of the Board members is subject to the circumstances specified in Paragraphs 3 and 4 of Article 26-3 of the Securities and Exchange Act. In addition, none of the Directors has a spousal relationship or a familial relationship within the second degree of kinship with any other Director.

The details are presented in the table below.

Board Diversity

The Company advocates for a policy of respecting board diversity. To strengthen corporate governance and promote the healthy development of the board’s composition and structure, we believe that the diversity policy helps enhance the Company’s overall performance. The selection of board members is based on merit and aims to incorporate a diverse range of capabilities across different industries, including basic conditions and values (e.g., gender, age), professional knowledge and skills (e.g., accounting, industry expertise, finance, marketing, or technology), as well as industry experience. Additionally, to fulfill our supervisory responsibilities, the company has established various internal management regulations to ensure robust governance functions.
The current board of directors consists of 9 members, including 5 non-independent directors and 4 independent directors. All directors are distinguished figures from both academia and industry. As a company in the medical technology industry, we emphasize the composition of our board members. We aim for one-half (50%) of the members to have expertise in biotechnology and healthcare, one-fifth (20%) to have expertise in finance, accounting, or law, and two-thirds (67%) to have expertise in business management, to ensure proper supervision and knowledge sharing. The current board composition already meets the Company’s expectations, and the implementation status is detailed in the table below:

According to the table above, the current gender ratio in our board of directors is 78% male and 22% female. This disparity is primarily due to the fact that the initial investors during the Company’s founding were predominantly male. In the future, during the re-election or expansion of board members, the Company will emphasize gender diversity, ensuring that the proportion of any single gender reaches one-third. This is in response to the “Sustainable Development Action Plan for Listed Companies” which promotes gender diversity on the boards of listed companies. The Company will also actively support the goals of gender balance and diversity and inclusion.

Implementation of Board Performance Evaluation

To implement corporate governance and enhance the functions of the Board of Directors, the Company approved the "Board of Directors Performance Evaluation Policy" on July 3, 2023. Starting from 2024, an internal evaluation is conducted at least once a year, and an external evaluation is expected to be carried out once every three years. In 2026, the 2025 performance of the Board of Directors and individual board members was evaluated using internal questionnaires. The execution status of the evaluation is shown in the table below:

The overall performance average score of the Board of Directors for 2025 was 4.98 points (out of a maximum of 5 points).

The overall performance average score of the Board members for 2025 was 4.98 points (out of a maximum of 5 points).

The evaluation results were reported at the 10 meeting of the 6^th Board of Directors on March 3, 2026.

Board Succession Planning and Implementation

The Company's Articles of Incorporation stipulate that the election of the Chairman and Directors shall adopt a candidate nomination system. In addition, the Corporate Governance Best Practice Principles and the Rules for Election of Directors provide that the composition of the Board of Directors shall take diversity into consideration. Diversity policies are formulated based on the Company's operations, business model, and development needs, including, but not limited to, criteria relating to fundamental qualifications and values, as well as professional knowledge and expertise.

The Company has established an ongoing succession plan for Directors (including the Chairman) by maintaining a database of potential Director candidates based on the following criteria:

1. Integrity, accountability, innovation, and sound decision-making, consistent with the Company's core values, together with professional knowledge and skills that contribute to the Company's management and operations. Such expertise includes legal affairs, accounting, industry experience, finance, marketing, technology, and other relevant professional backgrounds. The Company aims for at least 50% of Board members to possess expertise in biotechnology and healthcare, 20% to have expertise in finance, accounting, or law, and 67% to have business management expertise, thereby strengthening the Board's oversight function and facilitating knowledge sharing.

2. Gender diversity, with Directors of either gender accounting for at least one-third of the total Board seats.

3. Collective competencies of the Board, including:

• Business judgment

• Accounting and financial analysis

• Business management

• Crisis management

• Industry knowledge

• International market perspective

• Leadership

• Decision-making

The Company has also established the Board Performance Evaluation Policy, under which the Board's performance is assessed based on criteria including participation in the Company's operations, enhancement of Board decision-making quality, Board composition and structure, Director nomination and continuing education, internal control, and the expression of substantive opinions. These evaluations are conducted to ensure the effective operation of the Board, assess Directors' performance, and serve as an important reference for future Director nominations.